

VACCINE RESEARCH

PROGRAM AGENDA

MONDAY, APRIL 24, 2017

| | | |
|-----------------|---|----------------------|
| 7:00 AM-5:00 PM | Registration | Grand Ballroom Foyer |
| 7:00-8:00 AM | Poster Set-Up | Grand Ballroom Foyer |
| 7:30-8:30 AM | Continental Breakfast | Grand Ballroom Foyer |
| 8:30-9:30 AM | Opening Keynote K1 CE Moderator: Walter A. Orenstein, MD Emory University Atlanta, GA | Grand Ballroom E-H |
| | Greatest Vaccinology Discoveries of the Last Decade and Future Predictions Stanley A. Plotkin, MD University of Pennsylvania Vaxconsult Doylestown, PA | |
| 9:30-11:00 AM | Symposium 1: Challenges Implementing the World's First Licensed Dengue Vaccine S1-0 CE Moderator: Cristina G. Cassetti, PhD National Institute of Allergy and Infectious Diseases National Institutes of Health Rockville, MD | Grand Ballroom E-H |
| | 9:40-9:55 AM S1-1 Long Road to Preventing Dengue Disease by Vaccination, and Future Prospects Duane J. Gubler, ScD, MS Duke National University of Singapore Medical School Singapore | |
| | 9:55-10:10 AM S1-2 Biology of Antibody-Enhanced Dengue Disease: Evidence of Increased Risk After CYD-TDV Vaccination Scott B. Halstead, MD International Vaccine Institute Bethesda, MD | |

20TH ANNUAL CONFERENCE ON

PROGRAM AGENDA

10:10-10:25 AM | S1-3

Optimal Use of the First Licensed Dengue Vaccine: Balancing Benefit Against Potential Risks

Neil M. Ferguson, PhD
Imperial College London
London, England

10:25-10:40 AM | S1-4

Maximizing Benefit and Minimizing Risk for the World's First Licensed Dengue Vaccine: CYD-TDV

Timothy P. Endy, MD, MPH
State University of New York, Upstate Medical University
Syracuse, NY

10:40-11:00 AM

Questions and Answers

11:00-11:30 AM

Coffee Break

Grand Ballroom Foyer

11:30-1:00 PM

Symposium 2: Development and Approval Pathways of Vaccines For the Prevention of Emerging Infectious Diseases | S2-0 

Moderator: Kathleen M. Neuzil, MD, MPH
University of Maryland School of Medicine
Baltimore, MD

Grand Ballroom E-H

11:40-11:55 AM | S2-1

Epidemiology, Disease Burden, and Population Targets for Zika Vaccine

Marcos A. Espinal, MD, DrPH, MPH
Pan American Health Organization
Washington, DC

11:55 AM-12:10 PM | S2-2

BARDA Perspective about Challenges and Opportunities in Developing EID Vaccines

Ruben O. Donis, PhD
Biomedical Advanced Research and Development Authority
US Department of Health & Human Services
Washington, DC

12:10-12:25 PM | S2-3

Development and Approval Pathways for Vaccines to Prevent Emerging Infectious Diseases: FDA Regulatory Perspective

Marion F. Gruber, PhD
US Food and Drug Administration
Silver Spring, MD

VACCINE RESEARCH

PROGRAM AGENDA

12:25-12:40 PM | S2-4

Rapid Development of Candidate Zika Vaccines

Barney S. Graham, MD, PhD

National Institute of Allergy and Infectious Diseases

National Institutes of Health

Bethesda, MD

12:40-1:00 PM

Questions and Answers

1:00-2:00 PM

Lunch (on your own)

2:00-4:00 PM

Symposium 3: Therapeutic Vaccines for Addiction | S3-0 Grand Ballroom E-H

Moderator: Raphael Simon, PhD

University of Maryland School of Medicine

Baltimore, MD

2:10-2:40 PM | S3-1

Vaccination as a Means to Mitigate Drug Addiction

Kim D. Janda, PhD

The Scripps Research Institute

La Jolla, CA

2:40-3:10 PM | S3-2

Development of Vaccines to Prevent and Treat Addiction to Cocaine and Opiate Drugs

Thomas R. Kosten, MD

Baylor College of Medicine

Houston, TX

3:10-3:40 PM | S3-3

Treating Cocaine Addiction with Viral Vector for Cholinesterase in Mice, Rats, and Rhesus Monkeys

William S. Brimijoin, PhD

Mayo Clinic and Foundation

Rochester, MN

3:40-4:00 PM

Questions and Answers

4:00-4:30 PM

Coffee Break

Grand Ballroom Foyer

20TH ANNUAL CONFERENCE ON

PROGRAM AGENDA

| | | |
|--------------------------------|---|----------------------|
| 4:30-5:30 PM | Symposium 4: Human Challenge Models in Vaccine Development S4-0 CE Moderator: Marion F. Gruber, PhD US Food and Drug Administration Silver Spring, MD | Grand Ballroom E-H |
| | 4:35-4:55 PM S4-1 Scientific and Regulatory Aspects of Such Studies of Vaccines Wellington Sun, MD US Food and Drug Administration Silver Spring, MD | |
| | 4:55-5:15 PM S4-2 FDA Licensure of a Cholera Vaccine as a Result of Pivotal Efficacy Derived from Human Challenges Wilbur H. Chen, MD, MS University of Maryland School of Medicine Baltimore, MD | |
| | 5:15-5:30 PM Questions and Answers | |
| 5:30-6:30 PM | Welcome Reception & Poster Presentations | Grand Ballroom Foyer |
| TUESDAY, APRIL 25, 2017 | | |
| 7:00 AM-5:00 PM | Registration | Grand Ballroom Foyer |
| 7:30-8:30 AM | Poster Presentations & Continental Breakfast | Grand Ballroom Foyer |
| 8:30-9:30 AM | Mary Lou Clements-Mann Memorial Lecture in Vaccine Sciences K2 CE Moderator: Myron M. Levine, MD, DTPH University of Maryland School of Medicine Baltimore, MD | Grand Ballroom E-H |
| | D.A. Henderson Tribute: Legacy of Eradication Through Vaccines William H. Foege, MD, MPH Bill & Melinda Gates Foundation Seattle, WA | |
| 9:30-10:00 AM | Coffee Break | Grand Ballroom Foyer |

VACCINE RESEARCH

PROGRAM AGENDA

10:00-11:30 AM

Concurrent Sessions **CE**

Oral Abstracts 1: Epidemiology and Burden of Disease | OA1-0 **CE**

Moderator: Cyril G. Gay, DVM, PhD
US Department of Agriculture
Beltsville, MD

Grand Ballroom E

10:00-10:15 AM | OA1-1

Using the 4 Pillars™ Practice Transformation Program to Increase Adolescent Human Papillomavirus, Meningococcal, and Tetanus-Diphtheria-Pertussis Vaccination

Richard K. Zimmerman, MD, MPH, MA, MS
University of Pittsburgh
Pittsburgh, PA

10:15-10:30 AM | OA1-2

Antibody Responses to Zika Virus in Primary and Secondary Flavivirus Infections

Muktha S. Natrajan, PhD, MPH
Emory University
Atlanta, GA

10:30-10:45 AM | OA1-3

Modeling Reveals How Vaccination Could Significantly Reduce Hepatitis C Transmission via Syringe Sharing

Marian E. Major, PhD
US Food and Drug Administration
Silver Spring, MD

10:45-11:00 AM | OA1-4

Influence of e-Health Text Messages Linked to Health Portal on College Students' Influenza Vaccine Rate

Catherine A. Sharbaugh
Haverford College
Haverford, PA

11:00-11:15 AM | OA1-5

The Global Burden of Lower Respiratory Infections: Results from the Global Burden of Disease Study 2015

Chris E. Troeger, MPH
University of Washington
Seattle, WA

20TH ANNUAL CONFERENCE ON

PROGRAM AGENDA

11:15-11:30 AM | OA1-6

The Global Burden of Shigella and Enterotoxigenic *E. coli* Diarrhea

Ibrahim A. Khalil, MD, MPH
University of Washington
Seattle, WA

Oral Abstracts 2: Preclinical and Clinical Trials | OA2-0 **CE**

Moderator: Alison C. Mawle, PhD

Grand Ballroom F-H

Centers for Disease Control and Prevention
Atlanta, GA

10:00-10:15 AM | OA2-1

A Non-Glycosylated G Protein Vaccine Protects Against Homologous and Heterologous Respiratory Syncytial Virus Challenge in Both Mice and Cotton Rats

Surender Khurana, PhD
US Food and Drug Administration
Silver Spring, MD

10:15-10:30 AM | OA2-2

“Immune Focused” Influenza Vaccines Provide Better, Long-Lasting Cross-Protective Immunity Compared to IIV Against Pandemic H5 & H7 Highly Pathogenic Influenza Viruses

Surender Khurana, PhD
US Food and Drug Administration
Silver Spring, MD

10:30-10:45 AM | OA2-3

Sci-B-Vac, A Third Generation Hepatitis B Vaccine That Elicits Rapid and Robust Seroprotection in Adults

Francisco J. Diaz Mitoma, MD, PhD, FRCPC
VBI Vaccines, Inc.
Ottawa, Canada

10:45-11:00 AM | OA2-4

The IVAX Toolkit: Accelerating and Advancing Human and Animal Vaccine Design in Silico

Frances E. Terry, MPH
EpiVax
Providence, RI

11:00-11:15 AM | OA2-5

Genome-Wide Association Mapping of the Antibody Response to Diphtheria-Tetanus-Acellular Pertussis Vaccine in Mice

Yung-Yi C. Mosley, BVM, MS, PhD
Purdue University
West Lafayette, IN

VACCINE RESEARCH

PROGRAM AGENDA

11:15-11:30 AM | OA2-6

Immunogenicity, Safety of a Single Primary Dose of a Live Attenuated Japanese Encephalitis Recombinant Vaccine in Healthy Subjects in Vietnam

Vu D. Thiem, MD, PhD

National Institute of Hygiene and Epidemiology

Hanoi, Vietnam

11:30 AM-12:00 PM

Coffee Break

Grand Ballroom Foyer

12:00-1:00 PM

Awards Luncheon

Grand Ballroom E-H

Moderator: Walter A. Orenstein, MD

Emory Vaccine Center

Emory University

Atlanta, GA

12:10-12:30 PM

Robert Austrian Memorial Lecture | AL-1

Thinking Outside the Bug: An Admiral's Reflections on the Captain of the Men of Death

Anne Schuchat, MD (RADM, USPHS)

Centers for Disease Control and Prevention

Atlanta, GA

12:30-12:40 PM

Dr. Charles Mérieux Award for Achievement in Vaccinology and Immunology |

AL-2

Samuel L. Katz, MD

Duke University School of Medicine

Durham, NC

12:40-1:00 PM

Maurice R. Hilleman Early-Stage Career Investigator Award | AL-3

1:00-1:30 PM

Coffee Break

Grand Ballroom Foyer

1:30-3:00 PM

Concurrent Sessions 

Oral Abstracts 3: New and Emerging Vaccines (Part 1) | OA3-0 

Moderator: H. Keipp B. Talbot, MD, MPH

Vanderbilt University School of Medicine

Nashville, TN

Grand Ballroom E

20TH ANNUAL CONFERENCE ON

PROGRAM AGENDA

1:30-1:45 PM | OA3-1

Evolution of HIV-1 Env Open Trimer Conformation Driven by Peptide Fusion Inhibitor Resistance

Paul W. Keller, PhD
US Food and Drug Administration
Silver Spring, MD

1:45-2:00 PM | OA3-2

Effect of Influenza Vaccination on Lymphocyte Mirna Profiles

Richard B. Kennedy, PhD
Mayo Clinic and Foundation
Rochester, MN

2:00-2:15 PM | OA3-3

Identification of Highly Conserved Influenza a *HLA-A2* and *HLA-DR*-restricted T Cell Epitopes Capable of Inducing Robust Heterotypic Protective Immunity

Daniel F. Hoft, MD, PhD
Saint Louis University
St. Louis, MO

2:15-2:30 PM | OA3-4

Serum Antibody Profiling Following Vaccination with an Adjuvanted Thermostable Subunit Antigen Reveals a Possible Correlate of Immunity to Ricin Toxin

Jennifer L. Yates, PhD
Heath Research Inc.
Albany, NY

2:30-2:45 PM | OA3-5

Protection of Horse Foals Against the Tuberculosis-Like Pathogen *Rhodococcus Equi* via Conjugate Vaccine (AV0328)-Induced Maternal Antibody to Poly-N-Acetyl glucosamine

Gerald B. Pier, PhD
Brigham & Women's Hospital
Boston, MA

2:45-3:00 PM | OA3-6

Viral Vector-Based Prime/boost Regimen to Maximize Tissue-Resident Memory T Cell Responses for Therapeutic Vaccination Against HPV Cervicovaginal Neoplasia

Nicolas Çuburu, PhD
National Institutes of Health
National Cancer Institute
Bethesda, MD

VACCINE RESEARCH

PROGRAM AGENDA

Oral Abstracts 4: Vaccine Safety (Part 1) | OA4-0 **CE**

Grand Ballroom F-H

Moderator: Gregory A. Poland, MD
Mayo Clinic and Foundation
Rochester, MN

1:30-1:45 PM | OA4-1

Mapping the Morality of Vaccine Hesitance: Associations of Moral Foundation Values with Vaccine Hesitance

Avnika B. Amin
Emory University
Atlanta, GA

1:45-2:00 PM | OA4-2

Zika in the United States: Transmission and Strategies for Control

L. Beryl Guterman
Emory University
Atlanta, GA

2:00-2:15 PM | OA4-3

Safety of MenB-FHbp, a Meningococcal Serogroup B Vaccine, in US Young Adults: Results from a Phase 3 Study

John L. Perez, MD
Pfizer Vaccine Clinical Research
Collegeville, PA

2:15-2:30 PM | OA4-4

Safety of MenB-FHbp, a Meningococcal Serogroup B Vaccine, in US Adolescents: Results from a Phase 3 Study

John L. Perez, MD
Pfizer Vaccine Clinical Research
Collegeville, PA

2:30-2:45 PM | OA4-5

Genetic Diversity of Non-Structural Asibi/17d Mutant Yellow Fever Viruses

Natalie D. Collins, MPH
University of Texas Medical Branch
Galveston, TX

2:45-3:00 PM | OA4-6

Tumorigenicity of Spontaneously Immortalized Cells Used in Vaccine Manufacture: Responsiveness to Matrigel as a Possible Trait for Tumorigenicity Characterization

Haruhiko Murata, MD, PhD
US Food and Drug Administration
Silver Spring, MD

20TH ANNUAL CONFERENCE ON

PROGRAM AGENDA

3:00-3:30 PM **Coffee Break** Grand Ballroom Foyer

3:30-5:00 PM **Concurrent Sessions** **CE**

Oral Abstracts 5: New and Emerging Vaccines (Part 2) | OA5-0 **CE**

Moderator: Bruce G. Weniger, MD, MPH` Grand Ballroom E
Chiang Mai University
Chiang Mai, Thailand

3:30-3:45 PM | OA5-1

Willingness to Pay for an Ebola Vaccine Among a US National Sample During the Height of the 2014-2016 West African Ebola Outbreak

Julia E. Painter, PhD, MPH
George Mason University
Fairfax, VA

3:45-4:00 PM | OA5-2

Advancing the Clinical Development of GEN-003, a Therapeutic Vaccine for Recurrent Genital Herpes

Thomas C. Heineman, MD, PhD
Genocea Biosciences
Cambridge, MA

4:00-4:15 PM | OA5-3

A Two-Component DNA-Prime/Protein-Boost Vaccination Strategy for Eliciting Long-Term, Protective T Cell Immunity Against *Trypanosoma cruzi*

Nisha J. Garg, PhD, MBA
University of Texas Medical Branch
Galveston, TX

4:15-4:30 PM | OA5-4

Immune Response and Viral Persistence in Acute Human Zika Virus Infection – a Preliminary Report

Lilin Lai, MD
Emory University
Atlanta, GA

4:30-4:45 PM | OA5-5

Tools to Characterize the Immune Response to Zika Virus (ZIKV): Reporter Virus Particles, Anti-ZIKV MAbs, and Antibody Epitope Mapping

Edgar Davidson, PhD
Integral Molecular
Philadelphia, PA

VACCINE RESEARCH

PROGRAM AGENDA

4:45-5:00 PM | OA5-6

Human Antibody Repertoire Following VSV-Ebola Vaccination Identifies Novel Targets and Virus Neutralizing IgM Antibodies

Surender Khurana, PhD
US Food and Drug Administration
Silver Spring, MD

Oral Abstracts 6: Vaccine Safety (Part 2) | OA6-1 **CE**

Grand Ballroom F-H

Moderator: Karin Bok, MS, PhD

US Department of Health and Human Services
Washington, DC

3:30-3:45 PM | OA6-1

Nonclinical Investigations into the Reduced Effectiveness of the H1N1pdm09 Component of the Live Attenuated Influenza Vaccine

Oliver E. Dibben, PhD
MedImmune
Liverpool, England

3:45-4:00 PM | OA6-2

Evaluating Infant Mortality and Hospitalizations after Maternal Immunization in the Vaccine Safety Datalink, 2004-2014

Lakshmi Sukumaran, MD, MPH
Centers for Disease Control and Prevention
Atlanta, GA

4:00-4:15 PM | OA6-3

Recommended Immunization Schedule and All-Cause Mortality

Natalie L. McCarthy, MPH
Centers for Disease Control and Prevention
Atlanta, GA

4:15-4:30 PM | OA6-4

Adverse Events Following Quadrivalent Meningococcal CRM-Conjugate Vaccine Reported to the Vaccine Adverse Event Reporting System (VAERS), 2010-2015

Tanya R. Myers, PhD, MS
Emory University
Centers for Disease Control and Prevention
Atlanta, GA

4:30-4:45 PM | OA6-5

Feasibility of Examining Potential Mechanisms for Intussusception Following Rotavirus Vaccination in Infants 6-13 Weeks of Age

Mary A. Staat, MD, MPH
Cincinnati Children's Hospital Medical Center
Cincinnati, OH

20TH ANNUAL CONFERENCE ON

PROGRAM AGENDA

4:45-5:00 PM | OA6-6

Adverse Events Following Purified Chick Embryo Cell (PCEC, Rabavert®) Vaccine in the Vaccine Adverse Event Reporting System, 2006-2015

Pedro L. Moro, MD, MPH
Centers for Disease Control and Prevention
Atlanta, GA

5:30-7:00 PM

**Hilleman: A Perilous Quest to Save the World's Children
Movie Screening followed by Q&A with Producer**

Grand Ballroom E

Paul A. Offit, MD
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

WEDNESDAY, APRIL 26, 2017

7:00 AM-1:00 PM

Registration

Grand Ballroom Foyer

7:00-8:00 AM

Continental Breakfast

Grand Ballroom Foyer

7:00-7:45 AM

Dr. Richard J. Duma Meet the Experts Breakfast Sessions

Linden Oak (lower level)

Maximizing Benefit and Minimizing Risk for the World's First Licensed Dengue Vaccine: CYD-TDV

Timothy P. Endy, MD, MPH
State University of New York, Upstate Medical University
Syracuse, NY

Development and Approval Pathways for Vaccines to Prevent Emerging Infectious Diseases: FDA Regulatory Perspective

Marion F. Gruber, PhD
US Food and Drug Administration
Silver Spring, MD

Biology of Antibody-Enhanced Dengue Disease: Evidence of Increased Risk After CYD-TDV Vaccination

Scott B. Halstead, MD
International Vaccine Institute
Bethesda, MD

How to Get Published: Writing Effective Journal Articles

Gregory A. Poland, MD
Mayo Clinic and Foundation
Rochester, MN

Post-licensure Vaccine Safety Monitoring

Tom T. Shimabukuro, MD, MPH, MBA
Centers for Disease Control and Prevention
Atlanta, GA

VACCINE RESEARCH

PROGRAM AGENDA

Clinical Development of Synthetic DNA Vaccines: Advances in the Technology

David B. Weiner, PhD
Wistar Institute
Philadelphia, PA

8:00-10:00 AM

Symposium 5: Vaccine Innovations | S5-0

Grand Ballroom E-H

Moderator: Hana Golding, PhD
US Food and Drug Administration
Silver Spring, MD

8:10-8:30 AM | S5-1

Clinical Development of Synthetic DNA Vaccines: Advances in the Technology

David B. Weiner, PhD
Wistar Institute
Philadelphia, PA

8:30-8:50 AM | S5-2

mRNA-Based Vaccines Against HIV and Other Pathogens

Drew Weissman, MD, PhD
University of Pennsylvania
Philadelphia, PA

8:50-9:10 AM | S5-3

Structure-Based Immunogen Design for Flavivirus Vaccines

Felix A. Rey, PhD
Institut Pasteur
Paris, France

9:10-9:30 AM | S5-4

Recoding Structural Glycoprotein E2 in Classical Swine Fever Virus (CSFV) and Its Potential Use as a Vaccine Candidate

Lauro Velazquez, DVM, MS
Plum Island Animal Disease Center
Orient Point, NY

9:30-10:00 AM

Questions and Answers

10:00-10:30 AM

Coffee Break

20TH ANNUAL CONFERENCE ON

PROGRAM AGENDA

- 10:30 AM-12:30 PM **Symposium 6: Evaluating Vaccine Safety during Public Health Emergencies | S6-0** ^{CE}
Moderator: Saad B. Omer, MBBS, MPH, PhD Grand Ballroom E-H
Emory University & Emory Vaccine Center
Atlanta, GA
- 10:40-11:10 AM | S6-1**
Systematic Observational Method for Narcolepsy and Influenza Immunization Assessment (Somnia): Risk of Narcolepsy Following Adjuvanted 2009 H1N1 Influenza Vaccines
Tom T. Shimabukuro, MD, MPH, MBA
Centers for Disease Control and Prevention
Atlanta, GA
- 11:10-11:40 AM | S6-2**
Maintaining Public Confidence in Vaccines During a Pandemic
Daniel A. Salmon, PhD
Johns Hopkins Bloomberg School of Public Health
Baltimore, MD
- 11:40 AM-12:10 PM | S6-3**
Monitoring Influenza Vaccine Safety in Sentinel/Prism
Katherine Yih, PhD, MPH
Harvard Medical School and Harvard Pilgrim Health Care Institute
Boston, MA
- 12:10-12:30 PM**
Questions and Answers
- 12:30-1:30 PM **Lunch (on your own)**

VACCINE RESEARCH

PROGRAM AGENDA

1:30-2:30 PM

Closing Keynote

Grand Ballroom E-H

Vaccines to Fight Emerging Infectious Diseases: Use of Novel Platform Technologies | K3

(Note: No CE will be awarded for this session)

Moderator: Phyllis A. Arthur, MBA
Biotechnology Innovation Organization
Washington, DC

Presenters:

Marc-André D'Aoust, PhD
Medicago
Quebec, Canada

Christopher R. Heery, MD
Bavarian Nordic A/S
Washington, DC

Jeffrey B. Ulmer, PhD
GSK Vaccines
Washington, DC

David B. Weiner, PhD
Wistar Institute
Philadelphia, PA